Patent Application
20130171274
The present disclosure relates to a cosmetic composition for improving skin elasticity.
Structural changes of the epidermis, dermis, etc. result in reduced elasticity and drooping of the skin.
The thickness of the dermis decreases gradually. Total collagen content in the dermis decreases by 1% in a year after being adults and the remaining collagen fibers become gradually thicker, leading to increased crosslinking and decreased solubility, extensibility, etc.
In addition, elastin becomes thicker and more crosslinked. Besides, proliferative activity of fibroblasts in the dermis decreases whereas collagen synthesizing ability decreases and degrading ability increases.
As the regeneration of the epidermis, dermis, etc. becomes slow and the adhesion between the epidermis and the dermis becomes weak, the skin elasticity is decreased rapidly.
Although efforts have been made to improve the condition of skin elasticity and so on for women by increasing collagen or elastin, there have been few studies on the adhesion between the epidermis and the dermis.
The present disclosure is directed to providing a cosmetic composition for improving skin elasticity containing Phyllanthus urinaria extract and a polymersome in which an anti-aging peptide is stabilized as active ingredients and efficacious in improving skin wrinkles and restoring skin elasticity.
In one aspect, there is provided a cosmetic composition for improving skin elasticity containing Phyllanthus urinaria extract and a polymersome in which an anti-aging peptide is stabilized as active ingredients.
The cosmetic composition of the present disclosure is efficacious in improving skin wrinkles, restoring skin elasticity and increasing skin water content, and thus is effective for improving skin elasticity.
Exemplary embodiments now will be described more fully hereinafter with reference to the accompanying drawings, in which exemplary embodiments are shown.
The present disclosure provides a cosmetic composition for improving skin elasticity containing Phyllanthus urinaria and a polymersome in which an anti-aging peptide is stabilized as active ingredients.
Phyllanthus urinaria is also called chamberbitter, gripeweed and usually grows in fields or grasslands. Phyllanthus urinaria is known to be effective in treating enteritis, dysentery, edema caused by infectious hepatitis and nephritis, urinary tract infection, brightening eyes, infantile malnutrition, acute inflammation of eyes or corneal opacity, mouth ulcer, smallpox and occurrence of unknown furunculus in body and to provide a skin-whitening effect when included in cosmetics. Korean Patent Application Publication No. 2004-59004 discloses a skin whitening composition with inhibitory activity of melanogenesis, which contains one or more plant extracts selected from a group consisting of Phyllanthus urinaria extract, Alocasia cucullata extract and a mixture thereof as an active ingredient. And, Japanese Patent Publication No. H08-12566 discloses an inhibitor of tyrosinase activity containing one or more selected from a group consisting of Phyllanthus niruri L. extract, matico (Piper elongatum Vahl. & Piper ungustifolium) extract and Urtica urens extract.
The anti-aging peptide refers to a peptide exhibiting an anti-aging effect and may be, for example, palmitoyl tripeptide-5 or diaminopropionoyl tripeptide 33. The polymersome in which an anti-aging peptide is stabilized may be ABcell™ (Amorepacific).
A polymersome is an effective vesicle-type nanostructure synthesized from various amphiphilic polymers having both hydrophobic and hydrophilic blocks. In an aqueous solution, the amphiphilic polymers form aggregates according to the property of the hydrophilic blocks tending to aggregate together to decrease the free energy of the system. Since the hydrophilic blocks are uniformly dissolved in the aqueous solution, the polymersome may maintain a thermodynamically stable structure in the aqueous solution. The polymersome exhibits superior ability of penetrating into the skin and capturing active ingredients and is capable of maintaining the structure for a long period of time upon administration into the body because it is remarkably stable in aqueous solutions.
The composition of the present disclosure may increase expression of the perlecan gene and increase production of the perlecan protein. Perlecan is a proteoglycan existing in the epidermis and the dermis and has been found, with various growth factors attached thereto, to affect proliferation, differentiation and adhesion of epidermal cells. The composition of the present disclosure increases expression of the perlecan gene, thereby maintaining the skin structure by promoting regeneration of the epidermis and the dermis and the improvement of adhesion between the epidermis and the dermis. Accordingly, it may improve and restore skin elasticity.
Further, the composition restores production of the perlecan protein decreased by UV.
The composition of the present disclosure improves skin wrinkles, restores skin elasticity and increases skin water content.
Fibroblasts obtained from a newborn infant were seeded onto a 60-mm cell culture dish using DMEM containing 10% serum at a density of 1.25×106 cells/dish and cultured at 37° C. in a 5% CO2 incubator to about 80% confluency. After starvation for 24 hours, the cells were treated with Phyllanthus urinaria extract and ABcell™ at various concentrations, which had been washed twice with PBS, and cultured for 2 days. After removing the medium, RNA was isolated according to the Invitrogen's RNA separation method by adding 1 mL of Trizol (Invitrogen). After quantifying RNA at 260 nm using a UV detector (Hewlett Packard), reverse transcription-polymerase chain reaction (RT-PCR) was carried out. For genetic analysis of each sample, correction was made using the complementary 36B4 gene. The primer sequences of perlecan are as follows.
As seen from
Normal human fibroblasts were seeded onto a 60-mm cell culture dish using DMEM containing 10% serum at a density of 1.25×106 cells/dish and cultured at 37° C. in a 5% CO2 incubator to about 80% confluency. After starvation for 24 hours, the cells were washed twice with PBS and cultured for 2 days while irradiating UV B and treating with Phyllanthus urinaria extract. Then, increasing situation of the perlecan protein in cell status was investigated.
Adult human dermal fibroblasts (HDFa) purchased from Cascade Biologics (USA) were cultured using M106 medium (Cascade Biologics, USA) at 37° C. in a 5% CO2 incubator.
After spotting the cells onto a slide glass for immunofluorescence staining and treating with a substance for 48 hours, immunofluorescence staining was carried out. Details about the immunofluorescence staining are as follows. The cells were washed twice with DPBS and then fixed by treating with 3.5% paraformaldehyde for 10 minutes. The fixed cells were washed 3 times with DPBS, for 10 minutes each, and treated with 0.1% Triton X-100 for 5 minutes for permeation into the cells. After washing with PBS for 10 minutes, the cells were blocked with 5% goat serum for 30 minutes. After the blocking, the cells were treated with 5% goat serum with primary antibody added. Then, incubation was performed at room temperature for 1 hour so that the primary antibody (anti-perlecan antibody, Santa Cruz Biotechnology, USA) could bind to the corresponding antibody. After removing surplus primary antibody by washing 3 times with DPBS, for 10 minutes each, the cells were treated with secondary antibody at room temperature for 30 minutes. Surplus secondary antibody was completely removed by washing 3 times with DPBS, for 10 minutes each. After dropping one drop of a mounting solution onto a slide glass, followed by covering with a cover slip, the surplus mounting solution leaking out of the cover slip was removed and the cover slip was sealed.
Then, difference in fluorescence of each test group was observed using a confocal microscope.
As a result, it was confirmed that UV B resulted in decrease of perlecan and the Phyllanthus urinaria extract restored the production of perlecan decreased by UV (
Normal human fibroblasts (NHFs; isolated from adults in 20 and 40 years old) were seeded onto a 60-mm cell culture dish using DMEM containing 10% serum at a density of 1.25×106 cells/dish and cultured at 37° C. in a 5% CO2 incubator to about 80% confluency. The cultured cells were treated with 1% FBS medium+Cytokinol 100 ppm+10% BASF for 48 hours and observed after perlecan staining. ABcell™ was treated at a concentration of 10 ug/mL. The procedure was similar to that of Example 4.
A result of measuring fluorescence intensity is shown in Table 1 and
A clinical trial was conducted by Dermapro (Seongnam, Korea), an independent clinical trial institute, for the effect of improving skin wrinkles and elasticity of a cosmetic formulation containing Phyllanthus urinaria extract and ABcell. 40 women in their 30s and 40s were divided into two groups, 20 people each, and were asked to apply the formulation on the face twice a day, in the morning and evening, for 12 weeks. Then, improvement of skin wrinkles and elasticity were tested for 8 weeks using replicas according to arbitrary units (R1-R5).
The effect of improving skin wrinkles and elasticity was observed from 4 weeks after the application of the formulation (
Skin moisturizing effect of the formulations of Comparative Example 1 and Example 1 described in Table 2 was evaluated as follows. 40 women in their 30s and 40s were divided into two groups, 20 people each, and were asked to apply the formulation on the face twice a day, in the morning and evening, for 12 weeks. Then, skin water content was measured using a corneometer (Germany). The result is given in Table 3.
Phyllanthus
urinaria extract
Formulation examples of the cosmetic composition and the pharmaceutical composition according to the present disclosure are described below. However, the following examples are for illustrative purposes only and not intended to limit the scope of the present disclosure.
A softening lotion was prepared according to a commonly employed method with the composition described in Table 4.
Phyllanthus
urinaria extract
A nourishing lotion was prepared according to a commonly employed method with the composition described in Table 5.
Phyllanthus
urinaria extract
A nourishing cream was prepared according to a commonly employed method with the composition described in Table 6.
Phyllanthus
urinaria extract
A massage cream was prepared according to a commonly employed method with the composition described in Table 7.
Phyllanthus
urinaria extract
A pack was prepared according to a commonly employed method with the composition described in Table 8.
Phyllanthus
urinaria extract
A patch was prepared according to a commonly employed method with the composition described in Table 9.
Phyllanthus
urinaria extract
While the exemplary embodiments have been shown and described, it will be understood by those skilled in the art that various changes in form and details may be made thereto without departing from the spirit and scope of the present disclosure as defined by the appended claims.
In addition, many modifications can be made to adapt a particular situation or material to the teachings of the present disclosure without departing from the essential scope thereof. Therefore, it is intended that the present disclosure not be limited to the particular exemplary embodiments disclosed as the best mode contemplated for carrying out the present disclosure, but that the present disclosure will include all embodiments falling within the scope of the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2010-0084506 | Aug 2010 | KR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/KR2011/006405 | 8/30/2011 | WO | 00 | 2/28/2013 |
